Mr. Hashmall represents Teva Pharmaceuticals, the world’s largest generic pharmaceutical company, in Abbreviated New Drug Application (ANDA) litigations brought pursuant to the Hatch-Waxman Act and also in a wide variety of disputes involving licensing and joint-development agreements. His work for Teva has included leading Goodwin teams that:
- Secured a summary judgment ruling invalidating Pfizer’s Celebrex® patent and allowing Teva to market a generic version of the non-steroidal anti-inflammatory drug (U.S. District Court for the Eastern District of Virginia)
- Convinced the U.S. Court of Appeals for the Federal Circuit to invalidate all patent claims asserted by Pronova against Teva with respect to Teva’s ANDA to sell a generic version of Lovaza®, the first FDA-approved fish-oil derived prescription drug
- Secured a summary judgment ruling of non-infringement allowing Teva to market a generic version of the anticoagulant Lovenox® (U.S. District Court for the District of Massachusetts)
- Won a 16-day trial resulting in a judgment that the ANDAs filed by Sandoz/Momenta and Mylan infringe the patents covering Teva's branded product Copaxone®, the most prescribed treatment for relapse remitting multiple sclerosis (U.S. District Court for the Southern District of New York)
- Achieved multiple litigation victories, in a two-year legal battle, allowing for the early launch of Teva’s generic version of Eloxatin®, a colon cancer drug (U.S. District Court for the Districts of New Jersey and Columbia; U.S. Court of Appeals for the Federal and District of Columbia Circuits)
- Negotiated successful settlement after seven days of a jury trial involving Teva’s antitrust challenge of “product hopping” (i.e., making minor changes in drug formulations to prevent patents from expiring) by its competitors (U.S. District Court for the District of Delaware)
Mr. Hashmall is a member of the Law Firm Pro Bono Project Advisory Committee of the Pro Bono Institute, whose mission is to explore and identify new approaches to and resources for the provision of legal services to the poor and disadvantaged.